A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2‐Negative Breast Cancer

por Lim, Bora, Song, Juhee, Ibrahim, Nuhad K., Koenig, Kimberly B., Chavez‐MacGregor, Mariana, Ensor, Joe E., Gomez, Jill Schwartz, Krishnamurthy, Savitri, Caudle, Abigail S., Shaitelman, Simona F., Whitman, Gary J., Valero, Vicente
Publicado 2020